Back
 JBM  Vol.5 No.7 , July 2017
Role of Endotoxin and TNF in Developing NAFLD in Non-Obese Egyptian Patients
Abstract: Background and aim of the work: Non-alcoholic fatty liver disease (NAFLD) was considered the hepatic presentation of insulin resistance and obesity for a long time. Studies on lean weighted Asian subjects with NAFLD revealed that NAFLD pathogenesis may be multifactorial. NAFLD is associated with disturbances in gut flora and excess expression of inflammatory mediators. This study aims to find out the relation of endotoxins absorbed from gut and the tumor necrosis factor alpha with NAFLD in non-obese Egyptian patient in comparison to obese patients and healthy control subjects. Patients and methods: This study was performed on three groups group I: Patients with NAFLD and body mass index <25 kg/m2. Group II: Patients with NAFLD and body mass index >25 kg/m2. Group III: healthy control subjects. Results: Group I had significantly higher endotoxin, tumor necrosis factor(TNF) alpha and ALT than group II (endotoxin 11.7 ± 1.7 ug/L vs 9.5 ± 1.4) (TNF 14.8 ± 5.3 vs 11.3 ± 3.3) (ALT 67.8 ± 5.3 IU/L vs 51.8 ± 4.2). There was a highly significant correlation between TNF, endotoxin levels and level of liver enzymes in group I and II. Conclusion: Endotoxemia and TNF alpha may contribute in the pathogenesis of NAFLD especially in non-obese patients.
Cite this paper: Mostafa, E. , Farag, A. , Metwally, A. , Tantawy, E. and Omran, F. (2017) Role of Endotoxin and TNF in Developing NAFLD in Non-Obese Egyptian Patients. Journal of Biosciences and Medicines, 5, 7-15. doi: 10.4236/jbm.2017.57002.
References

[1]   Rinella, M.E. (2015) Nonalcoholic Fatty Liver Disease: A Systematic Review. JAMA (Systematic Review), 313, 2263-2273.
https://doi.org/10.1001/jama.2015.5370

[2]   McCulough, A.J. (2004) The Clinical Features, Diagnosis and Natural History of Nonalcoholic Fatty Liver Disease. Clinics in Liver Disease, 8, 521-533.
https://doi.org/10.1016/j.cld.2004.04.004

[3]   Adams, L.A. and Angulo, P. (2006) Treatment of Non-Alcoholic Fatty Liver Disease. Postgraduate Medical Journal, 82, 315-322.
https://doi.org/10.1136/pgmj.2005.042200

[4]   Petersen, K.F., Dufour, S., Hariri, A., Nelson-William, C., Foo, J.N., Zhang, X., Dziura, J., Lifton, R.P. and Shulman, G.I. (2010) Apolipoprotein C3 Gene Variants in Nonalcoholic Fatty Liver Disease. The New England Journal of Medicine, 362, 1082-1089.
https://doi.org/10.1056/NEJMoa0907295

[5]   Liu, C.J. (2012) Prevalence and Risk Factors for Non-Alcoholic Fatty Liver Disease in Asian People Who Are Not Obese. Journal of Gastroenterology and Hepatology, 27, 1555-1560.
https://doi.org/10.1111/j.1440-1746.2012.07222.x

[6]   Das, K., Das, K., Mukherjee, P.S., Ghosh, A., Ghosh, S., Mridha, A.R., Dhibar, T., Bhattacharya, B., Bhattacharya, D., Manna, B., Dhali, G.K., Santra, A. and Chowdhury, A. (2010) Nonobese Population in a Developing Country Has a High Prevalence of Nonalcoholic Fatty Liver and Significant Liver Disease. Hepatology, 51, 1593-1602.
https://doi.org/10.1002/hep.23567

[7]   Sabaté, J.M., Jouet, P., Harnois, F., Mechler, C., Msika, S., Grossin, M. and Coffin, B. (2008) High Prevalence of Small Intestinal Bacterial Overgrowth in Patients with Morbid Obesity: A Contributor to Severe Hepatic Steatosis. Obesity Surgery, 18, 371-377.
https://doi.org/10.1007/s11695-007-9398-2

[8]   Miele, L., Valenza, V., La Torre, G., Montalto, M., Cammarota, G., Ricci, R., Mascianà, R., Forgione, A., Ga-brieli, M.L., Perotti, G., Vecchio, F.M., Rapaccini, G., Gasbarrini, G., Day, C.P. and Grieco, A. (2009) Increased Intestinal Permeability and Tight Junction Alterations in Nonalcoholic Fatty Liver Disease. Hepatology, 49, 1877-1887.
https://doi.org/10.1002/hep.22848

[9]   Harte, A.L., da Silva, N.F., Creely, S.J., McGee, K.C., Billyard, T., Youssef-Elabd, E.M., Tripathi, G., Ashour, E., Abdalla, M.S., Sharada, H.M., Amin, A.I., Burt, A.D., Kumar, S., Day, C.P. and McTernan, P.G. (2010) Elevated Endotoxin Levels in Non-Alcoholic Fatty Liver Disease. Journal of Inflammation (Lond), 7, 15.
https://doi.org/10.1186/1476-9255-7-15

[10]   Akira, S., Uematsu, S. and Takeuchi, O. (2006) Pathogen Recognition and Innate Immunity. Cell, 124, 783-801.
https://doi.org/10.1016/j.cell.2006.02.015

[11]   Kiziltas, S. (2016) Toll-Like Receptors in Pathophysiology of Liver Diseases. World Journal of Hepatology, 8, 1354-1369.
https://doi.org/10.4254/wjh.v8.i32.1354

[12]   Rivera, C.A., Adegboyega, P., van Rooijen, N., Tagalicud, A., Allman, M. and Wallace, M. (2007) Toll-Like Receptor-4 Signaling and Kupffer Cells Play Pivotal Roles in the Pathogenesis of Non-Alcoholic Steatohepatitis. Journal of Hepatology, 47, 571-579.
https://doi.org/10.1016/j.jhep.2007.04.019

[13]   Hegazy, M. and Mostafa, A. (2012) Liver Ultrasound Scanning in the Detection of Hepatic Steatosis and Fibrosis in NASH Patients. The Egyptian Journal of Internal Medicine, 24, 27-31.

[14]   Matthews, D.R., Hosker, J.P., Rudenski, A.S., Naylor, B.A., Treacher, D.F. and Turner, R.C. (1985) Homeostasis Model Assessment: Insulin Resistance and Beta-Cell Function from Fasting Plasma Glucose and Insulin Concentrations in Man. Diabetologia, 28, 412-419.
https://doi.org/10.1007/BF00280883

[15]   Wattacheril, J. and Sanyal, A.J. (2016) Lean NAFLD: An Underrecognized Outlier. Current Hematology Reports, 15, 134-139.
https://doi.org/10.1007/s11901-016-0302-1

[16]   Alam, S., Gupta, U.D., Alam, M., Kabir, J., Chowdhury, Z.R. and Alam, A.K. (2014) Clinical, Anthropometric, Biochemical, and Histological Characteristics of Nonobese Nonalcoholic Fatty Liver Disease Patients of Bangladesh. Indian Journal of Gastroenterology, 33, 452-457.
https://doi.org/10.1007/s12664-014-0488-5

[17]   Das, K. and Chowdhury, A. (2013) Lean NASH: Distinctiveness and Clinical Implication. Hepatology International, 7, 806-813.

[18]   Jarrar, M.H., Baranova, A., Collantes, R., Ranard, B., Stepanova, M., Bennett, C., Fang, Y., Elariny, H., Goodman, Z., Chandhoke, V. and Younossi, Z.M. (2008) Adipokines and Cytokines in Non-Alcoholic Fatty Liver Disease. Alimentary Pharmacology & Therapeutics, 27, 412-421.
https://doi.org/10.1111/j.1365-2036.2007.03586.x

[19]   Ceccarelli, S., Panera, N., Mina, M., Gnani, D., De Stefanis, C., Crudele, A., Rychlicki, C., Petrini, S., Bruscalupi, G., Agostinelli, L., Stronati, L., Cucchiara, S., Musso, G., Furlanello, C., Svegliati-Baroni, G., Nobili, V. and Alisi, A. (2015) LPS-Induced TNF-α Factor Mediates Pro-Inflammatory and Pro-Fibrogenic Pattern in Non-Alcoholic Fatty Liver Disease. Oncotarget, 6, 41434-41452.

[20]   duPlessis, J., Korf, H., van Pelt, J., Windmolders, P., Vander Elst, I., Verrijken, A., Hubens, G., Van Gaal, L., Cassiman, D., Nevens, F., Francque, S., and van der Merwe, S. (2016) Pro-Inflammatory Cytokines but Not Endotoxin-Related Parameters Associate with Disease Severity in Patients with NAFLD. PLoS ONE, 11, e0166048.

[21]   Ruiz, A.G., Casafont, F., Crespo, J., Cayón, A., Mayorga, M., Estebanez, A., Fernadez-Escalante, J.C. and Pons-Romero, F. (2007) Lipopolysaccharide-Binding Protein Plasma Levels and Liver TNF-Alpha Gene Expression in Obese Patients: Evidence for the Potential Role of Endotoxin in the Pathogenesis of Non-Alcoholic Steatohepatitis. Obesity Surgery, 17, 1374-1380.
https://doi.org/10.1007/s11695-007-9243-7

 
 
Top